--- title: "Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?" type: "News" locale: "en" url: "https://longbridge.com/en/news/291170185.md" description: "Adaptive Biotechnologies (ADPT) announced plans to split its Minimal Residual Disease and Immune Medicine businesses, alongside a $300 million zero coupon convertible notes offering. The stock has seen strong recent momentum, with a 38.35% return over 30 days. However, analysis suggests the stock is slightly overvalued at $20.96 versus a fair value of $20.14, citing risks like continued losses and reliance on key partnerships despite improved profitability in the MRD segment." datetime: "2026-06-29T15:51:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291170185.md) - [en](https://longbridge.com/en/news/291170185.md) - [zh-HK](https://longbridge.com/zh-HK/news/291170185.md) --- # Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full? Adaptive Biotechnologies (ADPT) is back in focus after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses, alongside completing a $300 million zero coupon convertible notes offering. See our latest analysis for Adaptive Biotechnologies. These separation plans and the recent convertible notes offering come on the back of strong momentum in Adaptive Biotechnologies' stock, with a 30 day share price return of 38.35% and a 1 year total shareholder return of 79.91%, although the 5 year total shareholder return is down 46.68%, indicating a mixed longer term picture. If you are looking beyond Adaptive Biotechnologies for other ways to position around healthcare and AI trends, it may be worth scanning 40 healthcare AI stocks With Adaptive Biotechnologies now pursuing a business separation and fresh funding via zero coupon convertible notes, yet trading slightly above one analyst price target and an estimated intrinsic value, the key question is: is there still a buying opportunity here, or is the market already pricing in future growth? ## Most Popular Narrative: 4.1% Overvalued With Adaptive Biotechnologies' last close at $20.96 versus a most-followed fair value of $20.14, the narrative now frames the stock as slightly ahead of that central estimate while hinging heavily on the MRD business. > _Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise._ Read the complete narrative. Curious what underpins that $20.14 fair value for Adaptive Biotechnologies? The narrative leans on brisk revenue expansion, a future profit margin reset, and a rich earnings multiple that would usually be reserved for higher growth leaders. The full story connects those assumptions into one tight earnings path and a valuation bridge that investors will want to see in detail. **Result: Fair Value of $20.14 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear pressure points, including continued losses at Adaptive Biotechnologies and reliance on a handful of key partnerships that could disrupt the current fair value story. Find out about the key risks to this Adaptive Biotechnologies narrative. ## Next Steps With sentiment on Adaptive Biotechnologies split between concern and optimism, it makes sense to move quickly and stress test the details for yourself, starting with the 2 key rewards and 1 important warning sign. ## Looking for more investment ideas beyond Adaptive Biotechnologies? If you are serious about building a stronger portfolio, do not stop at Adaptive Biotechnologies. Use focused stock lists to uncover ideas that fit your goals. - Zero in on potential value opportunities by scanning 44 high quality undervalued stocks that pair quality fundamentals with what may be appealing entry prices. - Prioritize stability and downside protection as you review 69 resilient stocks with low risk scores that score well on resilience and risk metrics. - Hunt for potential future leaders hiding in plain sight by checking the screener containing 19 high quality undiscovered gems before others catch on. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ADPT.US](https://longbridge.com/en/quote/ADPT.US.md) ## Related News & Research - [Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 1,299 common shares for $31,176](https://longbridge.com/en/news/294743960.md) - [Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates](https://longbridge.com/en/news/294255863.md) - [152,500 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Perceptive Advisors LLC](https://longbridge.com/en/news/294603584.md) - [Caxton Associates LLP Has $500,000 Stake in Adaptive Biotechnologies Corporation $ADPT](https://longbridge.com/en/news/294025220.md) - [Arrowhead Pharma acquires FDA rare pediatric disease priority review voucher](https://longbridge.com/en/news/294869347.md)